CAMBRIDGE, Mass., August 1, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation in the Barclays Biotech: 1×1 Private Company Symposium on Wednesday, August 7, 2024.

This event is being held in a virtual format during which Company management will participate in one-on-one meetings with investors.

About Myeloid Therapeutics

Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.

For additional information, please visit https://myeloidtx.com/ and follow us on LinkedIn and X/Twitter. For collaborative interests, write to [email protected].